ABOUT US
WHO WE ARE
Lextro Labs was established in year 2022, at Genome Valley, a vibrant biotech cluster in the city of Hyderabad, India.
The driving force at Lextro Labs is a deep-rooted belief that human lives can be transformed through continuous scientific innovation. Witnessing the challenges faced by patients battling devastating diseases, we recognized the pressing need for advanced therapies that go beyond conventional approaches, and embarked on the journey to develop ground-breaking biotherapeutics that hold the potential to change lives.
VISION
To develop advanced therapeutics that rejuvenate life and bring hope and healing to patients by pushing the boundaries of medical innovation
MISSION
Our mission is to develop multi-specific biopharmaceuticals that restore immune homeostasis mechanisms, alleviating pain and suffering in patients with unmet medical needs. By focusing on immune modulation and cytotoxicity, we seek to address the root causes of diseases and provide effective solutions for patients worldwide.
VALUES
SCIENTIFIC EXCELLENCE
We strive to advance the field of biotherapeutics through rigorous scientific inquiry, innovation, and continuous improvement
INTEGRITY & ETHICS
We are transparent, honest, and accountable in our interactions with all our stakeholders; and committed to patient safety, data integrity, and compliance with regulatory requirements
COLLABORATION & PARTNERSHIP
We actively seek collaborations with industry, NGO’s, academia, healthcare providers, regulatory bodies, and other stakeholders; we place our trust in the power of collective intelligence to drive innovation and accelerate the development of
life-saving therapies
SUSTAINABILITY & SOCIAL RESPONSIBILITY
We strive to minimize our ecological footprint, promote responsible resource management; we emphasise on ethical business practices, diversity and inclusion, and support initiatives that benefit the society at large
LEADERSHIP
Akkina Srinivas Chowdary
MCA, MBA
founder & Managing Director
Akkina Srinivas Chowdary, an MBA, is the Director of Venkateshwara Minerals since 2006. He has successfully led the company’s growth and expansion into new areas – evolving from mining, logistics and financial investments into futuristic, new age businesses like biologics. Lextro leverages his vision and expertise to tap into new markets and revenue streams. Passionate about sports and grooming talent, he has helped provide sports facilities and serves as the President of the Football Association in his district.
Murali K Addepalli
PhD
Co-founder & Chief Scientific Officer
Dr. Murali K Addepalli has 20+ years’ experience in drug discovery and development of novel immune-therapeutics for oncology, autoimmune and infectious diseases. After obtaining his PhD from Nagasaki University (Japan), he gained valuable experience at NIH, Bethesda (USA) as a Post-doctoral Fellow. He has a proven track record of creating therapeutic pipelines and generating a significant IP portfolio (9 patents) at leading Big Pharma companies including Nektar Therapeutics, Biocon Bristol Myers Squibb and Reliance Life Sciences. He worked in 15+ discovery programs in various capacities, including Biology Lead, Program Lead, and was instrumental in several IND filings.
On the scientific side, Murali has amassed experience in the areas of recombinant therapeutic protein expression, translational research for understanding MoA as well as biomarker discovery, vaccine development, design of molecules using in-silico approaches and tools, development of novel therapeutic monoclonal antibodies from natural & random paired libraries, and NCE & NBE screening in PDO & PDX models. He has special interest in designing new concepts in drug discovery and repurposing drugs. He has more than 25+ publications in reputed journals such as J Immunother Cancer, Nature Commun., Clin. Cancer. Res., Gene therapy, Angiogenesis etc.
On the management side, he is responsible for P&L of contract/custom research projects, has expertise in management and delivery of large global discovery programs, and contributes to optimizing outsourcing strategies to CROs and expediting research timelines.
During his tenure as the Chairperson of IACUC and Biosafety Committee, Murali was instrumental in securing AAALAC for the host organization. He also oversaw the IND documentation for accuracy and to meet FDA requirements, evaluated the in-licensing of molecules and technologies and participated in the out-licensing activities.
